Collage photo of Mateo Mejia, Ruben Niesvizky and Mark Bustoros
Aug 12, 2024, 03:20
Using lymphocyte count to predict CAR-T cell therapy efficacy in relapsed multiple myeloma
WCM Myeloma Center posted on X:
“New research led by Drs. Mateo Mejia, Ruben Niesvizky and Mark Bustoros showed that a simple blood test may help predict whether patients with relapsed Multiple Myeloma will respond to chimeric antigen (CAR) T-cell therapy.”
Read Further.
Source: WCM Myeloma Center/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 16:29
Nov 14, 2024, 16:27
Nov 14, 2024, 16:22
Nov 14, 2024, 16:22
Nov 14, 2024, 16:13
Nov 14, 2024, 16:03
Nov 14, 2024, 15:58
Nov 14, 2024, 15:54
Nov 14, 2024, 15:53